Demo
SEC_FILINGS_XXY_PRO
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer’s Disease
POTOMAC, Md., September 4, 2024 — IGC Pharma, Inc. (NYSE American: IGC) (“IGC Pharma” or the “Company”) announced today that the Company is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer’s disease. Following the FDA’s 2023 approval of two groundbreaking anti-amyloid drugs, Donanemab (Eli Lilly) and Lecanemab […]